outcomes in high-risk cll patients following fixed-duration treatment with ibrutinib plus venetoclax
Published 10 months ago • 545 plays • Length 2:43Download video MP4
Download video MP3
Similar videos
-
2:00
obinutuzumab, ibrutinib, and venetoclax in high-risk cll: the cll2-give and cll13 trials
-
1:48
patient risk stratification in cll and selection of treatment approaches
-
3:13
selection for time-limited & continuous therapy in cll
-
2:55
clinical outcomes of patients with cll receiving long-term ibrutinib in the resonate-2 study
-
2:54
the definition of high-risk cll
-
1:05
long-term outcomes of patients with cll treated with continuous ibrutinib
-
2:39
the safety and efficacy of ibrutinib for the treatment of cll
-
4:02
living with chronic lymphocytic leukaemia (cll)
-
7:24
what are the current cll treatment options?
-
7:55
clinical trials of fixed duration treatments & novel targets in cll
-
1:29
the importance of treatment sequencing in cll
-
3:09
mrd outcomes from glow: venetoclax and ibrutinib in cll
-
1:38
ibrutinib and venetoclax upfront for high-risk cll
-
2:36
treatment approaches to cll with high-risk molecular features
-
1:22
long-term outcomes and toxicities of ibrutinib in cll
-
1:20
improving patient outcomes in ctcl: clinical collaboration and novel agents
-
1:12
insights into the optimal management of cll: the importance of patient characteristics
-
2:19
long-term management of cll for improved outcomes
-
10:20
eha22: time-limited venetoclax-obinutuzumab /- ibrutinib is superior to chemoimmunotherapy in ...
-
0:56
the current treatment landscape in cll
-
2:20
the effect of ibrutinib dose-reduction on outcomes of patients with cll/sll: real-world evidence
-
4:31
sequence of administration of ibrutinib with obinutuzumab in r/r cll patients